Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608582 · ClinicalTrials.gov registry record · Phase 1
Transcranial Magnetic Stimulation to Improve Speech in Aphasia
A Phase 1 study, sponsored by Boston University.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00608582: Completed Phase 1 study, sponsored by Boston University.
NCT00608582 is a Phase 1 study that has completed, run by Boston University. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608582, a Phase 1 study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether repetitive transcranial magnetic stimulation (rTMS) can be used to improve speech in chronic stroke patients with aphasia. Aphasia patients can have problems with speech production. The rTMS procedure allows painless, noninvasive stimulation of human cortex from outside the head. Chronic aphasia patients have been observed in our functional magnetic resonance brain imaging studies to have excess brain activation in brain areas possibly related to language on the right side of the brain (opposite side to where the stroke took place). It is expected that suppression of activity in the directly targeted brain region will have an overall modulating effect on the neural network for naming (and propositional speech) and will result in behavioral improvement.
Primary Outcome
Pictures named correctly on Boston Naming Test (BNT), First 20 Pictures
Interventions
- DEVICE Transcranial Magnetic Stimulation, Repetitive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2002-07 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT00608582 record still lists
NCT00608582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Transcranial Magnetic Stimulation, Repetitive is the first listed.
NCT00608582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608582 about?
NCT00608582 is a clinical study titled "Transcranial Magnetic Stimulation to Improve Speech in Aphasia". The purpose of this study is to examine whether repetitive transcranial magnetic stimulation (rTMS) can be used to improve speech in chronic stroke patients with aphasia. Aphasia patients can have problems with speech production. The rTMS procedure allows painless, noninvasive stimulation of human c...
What is the current status of trial NCT00608582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2002-07. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00608582?
The interventions under investigation include: Transcranial Magnetic Stimulation, Repetitive (DEVICE).
Who is sponsoring clinical trial NCT00608582?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608582's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia